MBRX

Moleculin Biotech, Inc.

4.40 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Moleculin Biotech, Inc. stock is down -10.57% since 30 days ago. The next earnings date is Aug 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 8 June’s closed higher than May.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the. treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in clinical trials for brain tumors and pediatric brain tumors.